Skip to main content

Advertisement

SpringerLink
Log in

Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder

  • Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Among individuals with multiple sclerosis (MS), mental health comorbidities play a significant role in contributing to secondary disability and detracting from quality of life. This review examines current evidence surrounding three mental health issues of particular relevance to MS: depression, anxiety, and bipolar disorder. We review what is known of the prevalence, correlates, screening mechanisms, and current treatment of each issue and provide recommendations for future areas of research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently have been highlighted as: • Of importance

  1. Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21(3):305–17.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10(9):507–17.

    Article  PubMed  Google Scholar 

  3. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61(11):1524–7.

    Article  CAS  PubMed  Google Scholar 

  4. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002;159(11):1862–8.

    Article  PubMed  Google Scholar 

  5. • Marrie RA, Fisk JD, Tremlett H, et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology. 2015;85(22):1972–9. This study compared the incidence and prevalence of psychiatric comorbidity in the multiple sclerosis (MS) population and in controls matched for age, sex, and geographic area. It concluded that psychiatric comorbidity is common in MS, and more frequently affected the MS population than a matched population, although the incidence was stable over time. Men with MS face a disproportionately greater relative burden of depression when they develop MS than women.

  6. Foley FW, Traugott U, LaRocca NG, Smith CR, Perlman KR, Caruso LS, et al. A prospective study of depression and immune dysregulation in multiple sclerosis. Arch Neurol. 1992;49(3):238–44.

    Article  CAS  PubMed  Google Scholar 

  7. Fassbender K, Schmidt R, Mossner R, Kischka U, Kuhnen J, Schwartz A, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol. 1998;55(1):66–72.

    Article  CAS  PubMed  Google Scholar 

  8. Rudick RA, Ransohoff RM. Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch Neurol. 1992;49(3):265–70.

    Article  CAS  PubMed  Google Scholar 

  9. Arnason B. The role of cytokines in multiple sclerosis. Neurology. 1995;45(6 Suppl 6):S54–5.

    Article  CAS  PubMed  Google Scholar 

  10. Karege FBG, Verhagen M, van der Meij A, van Deurzen PA, et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry. 2010;15:260–71.

    Article  CAS  Google Scholar 

  11. Rawson KS, Dixon D, Nowotny P, Ricci WM, Binder EF, Rodebaugh TL, et al. Association of functional polymorphisms from brain-derived neurotrophic factor and serotonin-related genes with depressive symptoms after a medical stressor in older adults. PLoS One. 2015;10(3):e0120685.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Pei Y, Smith AK, Wang Y, Pan Y, Yang J, Chen Q, et al. The brain-derived neurotrophic-factor (BDNF) val66met polymorphism is associated with geriatric depression: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(5):560–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Santoro M, Nociti V, De Fino C, Caprara A, Giordano R, Palomba N, et al. Depression in multiple sclerosis: effect of brain derived neurotrophic factor Val66Met polymorphism and disease perception. Eur J Neurol. 2016;23(3):630–40.

    Article  CAS  PubMed  Google Scholar 

  14. Vattakatuchery JJ, Rickards H, Cavanna AE. Pathogenic mechanisms of depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2011;23(3):261–76.

    Article  CAS  PubMed  Google Scholar 

  15. Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport. 2000;11(6):1153–8.

    Article  CAS  PubMed  Google Scholar 

  16. Ricelli R PL, Cerasa A, Nigro S, Cavalli SM, Chiriaco C, Valentino P, Nistico R, Quattrone A. Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients. Mult Scler. 2015.

  17. Nigro S, Passamonti L, Riccelli R, Toschi N, Rocca F, Valentino P, et al. Structural ‘connectomic’ alterations in the limbic system of multiple sclerosis patients with major depression. Mult Scler. 2015;21(8):1003–12.

    Article  PubMed  Google Scholar 

  18. Gobbi C, Rocca MA, Pagani E, Riccitelli GC, Pravata E, Radaelli M, et al. Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis. Mult Scler. 2014;20(12):1633–40.

    Article  CAS  PubMed  Google Scholar 

  19. Feinstein A. Multiple sclerosis and depression. Mult Scler. 2011;17(11):1276–81.

    Article  PubMed  Google Scholar 

  20. Yaldizli O, Penner IK, Yonekawa T, et al. The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis. Eur J Neurol. 2016;23(3):510–9.

    Article  CAS  PubMed  Google Scholar 

  21. Feinstein A, Roy P, Lobaugh N, Feinstein K, O’Connor P, Black S. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology. 2004;62(4):586–90.

    Article  CAS  PubMed  Google Scholar 

  22. Ron MA, Logsdail SJ. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol Med. 1989;19(4):887–95.

    Article  CAS  PubMed  Google Scholar 

  23. Moller A, Wiedemann G, Rohde U, Backmund H, Sonntag A. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand. 1994;89(2):117–21.

    Article  CAS  PubMed  Google Scholar 

  24. Jones KH, Ford DV, Jones PA, John A, Middleton RM, Lockhart-Jones H, et al. A large-scale study of anxiety and depression in people with multiple sclerosis: a survey via the web portal of the UK MS Register. PLoS One. 2012;7(7):e41910.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Zabad RK, Patten SB, Metz LM. The association of depression with disease course in multiple sclerosis. Neurology. 2005;64(2):359–60.

    Article  PubMed  Google Scholar 

  26. Patten SB, Lavorato DH, Metz LM. Clinical correlates of CES-D depressive symptom ratings in an MS population. Gen Hosp Psychiatry. 2005;27(6):439–45.

    Article  PubMed  Google Scholar 

  27. Ensari I, Adamson BC, Motl RW. Longitudinal association between depressive symptoms and walking impairment in people with relapsing-remitting multiple sclerosis. J Health Psychol. 2015.

  28. Williams RM, Turner AP, Hatzakis Jr M, Bowen JD, Rodriquez AA, Haselkorn JK. Prevalence and correlates of depression among veterans with multiple sclerosis. Neurology. 2005;64(1):75–80.

    Article  CAS  PubMed  Google Scholar 

  29. Moore P, Hirst C, Harding KE, Clarkson H, Pickersgill TP, Robertson NP. Multiple sclerosis relapses and depression. J Psychosom Res. 2012;73(4):272–6.

    Article  PubMed  Google Scholar 

  30. Archibald CJ, Fisk JD. Information processing efficiency in patients with multiple sclerosis. J Clin Exp Neuropsychol. 2000;22(5):686–701.

    Article  CAS  PubMed  Google Scholar 

  31. Benedict RH, Cookfair D, Gavett R, Gunther M, Munschauer F, Garg N, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006;12(4):549–58.

    Article  PubMed  Google Scholar 

  32. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139–51.

    Article  PubMed  Google Scholar 

  33. Parmenter BA, Zivadinov R, Kerenyi L, et al. Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J Clin Exp Neuropsychol. 2007;29(2):215–23.

    Article  PubMed  Google Scholar 

  34. Kinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology. 2010;24(5):573–80.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Maor Y, Olmer L, Mozes B. The relation between objective and subjective impairment in cognitive function among multiple sclerosis patients—the role of depression. Mult Scler. 2001;7(2):131–5.

    CAS  PubMed  Google Scholar 

  36. Benedict RH, Bruce JM, Dwyer MG, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol. 2006;63(9):1301–6.

    Article  PubMed  Google Scholar 

  37. Arnett PA, Higginson CI, Voss WD, Wright B, Bender WI, Wurst JM, et al. Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning. Neuropsychology. 1999;13(3):434–46.

    Article  CAS  PubMed  Google Scholar 

  38. Diamond BJ, Johnson SK, Kaufman M, Graves L. Relationships between information processing, depression, fatigue and cognition in multiple sclerosis. Arch Clin Neuropsychol. 2008;23(2):189–99.

    Article  PubMed  Google Scholar 

  39. Rabinowitz AR, Arnett PA. A longitudinal analysis of cognitive dysfunction, coping, and depression in multiple sclerosis. Neuropsychology. 2009;23(5):581–91.

    Article  PubMed  Google Scholar 

  40. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994;21(1):9–14.

    Article  CAS  PubMed  Google Scholar 

  41. Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler. 2001;7(5):340–4.

    Article  CAS  PubMed  Google Scholar 

  42. Ben Ari Shevil E, Johansson S, Ytterberg C, Bergstrom J, von Koch L. How are cognitive impairment, fatigue and signs of depression related to participation in daily life among persons with multiple sclerosis? Disabil Rehabil. 2014;36(23):2012–8.

    Article  PubMed  Google Scholar 

  43. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci. 2005;231(1–2):29–34.

    Article  PubMed  Google Scholar 

  44. Wood B, van der Mei IA, Ponsonby AL, Pittas F, Quinn S, Dwyer T, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler. 2013;19(2):217–24.

    Article  CAS  PubMed  Google Scholar 

  45. Gobbi C, Rocca MA, Riccitelli G, Pagani E, Messina R, Preziosa P, et al. Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Mult Scler. 2014;20(2):192–201.

    Article  CAS  PubMed  Google Scholar 

  46. Turner AP, Williams RM, Bowen JD, Kivlahan DR, Haselkorn JK. Suicidal ideation in multiple sclerosis. Arch Phys Med Rehabil. 2006;87(8):1073–8.

    Article  PubMed  Google Scholar 

  47. Viner R, Patten SB, Berzins S, Bulloch AG, Fiest KM. Prevalence and risk factors for suicidal ideation in a multiple sclerosis population. J Psychosom Res. 2014;76(4):312–6.

    Article  PubMed  Google Scholar 

  48. Bronnum-Hansen H, Stenager E, Nylev Stenager E, Koch-Henriksen N. Suicide among Danes with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76(10):1457–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Fredrikson S, Cheng Q, Jiang GX, Wasserman D. Elevated suicide risk among patients with multiple sclerosis in Sweden. Neuroepidemiology. 2003;22(2):146–52.

    Article  CAS  PubMed  Google Scholar 

  50. Manouchehrinia A, Tanasescu R, Tench CR, Constantinescu CS. Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. J Neurol Neurosurg Psychiatry. 2016;87(3):324–31.

    Article  PubMed  Google Scholar 

  51. Stenager EN, Stenager E, Koch-Henriksen N, Bronnum-Hansen H, Hyllested K, Jensen K, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry. 1992;55(7):542–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry. 1998;65(1):56–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002;59(5):674–8.

    Article  PubMed  Google Scholar 

  54. Flood S, Foley FW, Zemon V, Picone M, Bongardino M, Quinn H. Predictors of changes in suicidality in multiple sclerosis over time. Disabil Rehabil. 2014;36(10):844–7.

    Article  PubMed  Google Scholar 

  55. Stenager EN, Koch-Henriksen N, Stenager E. Risk factors for suicide in multiple sclerosis. Psychother Psychosom. 1996;65(2):86–90.

    Article  CAS  PubMed  Google Scholar 

  56. Sibley WA, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655–61.

    Article  Google Scholar 

  57. Jacobs LD, Beck RW, Simon JH, Kinkel RP, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343(13):898–904.

    Article  CAS  PubMed  Google Scholar 

  58. Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression: a prospective investigation. J Neurol. 2002;249(7):815–20.

    Article  PubMed  Google Scholar 

  59. Patten SB, Metz LM. Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler. 2001;7(4):243–8.

    CAS  PubMed  Google Scholar 

  60. Patten SB, Metz LM, Group SS. Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology. 2002;59(5):744–6.

    Article  CAS  PubMed  Google Scholar 

  61. The World Health Organization Quality of Life Group. The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med. 1998;46(12):1569–85.

    Article  Google Scholar 

  62. D’Alisa S, Miscio G, Baudo S, Simone A, Tesio L, Mauro A. Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study. Disabil Rehabil. 2006;28(5):307–14.

    Article  PubMed  Google Scholar 

  63. Patti F, Cacopardo M, Palermo F, Ciancio MR, Lopes R, Restivo D, et al. Health-related quality of life and depression in an Italian sample of multiple sclerosis patients. J Neurol Sci. 2003;211(1–2):55–62.

    Article  PubMed  Google Scholar 

  64. Fernandez-Jimenez E, Arnett PA. Impact of neurological impairment, depression, cognitive function and coping on quality of life of people with multiple sclerosis: a relative importance analysis. Mult Scler. 2015;21(11):1468–72.

    Article  CAS  PubMed  Google Scholar 

  65. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci. 2002;205(1):51–8.

    Article  PubMed  Google Scholar 

  66. Janssens AC, van Doorn PA, de Boer JB, Kalkers NF, van der Meche FG, Passchier J, et al. Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler. 2003;9(4):397–403.

    Article  CAS  PubMed  Google Scholar 

  67. Kisic Tepavcevic D, Pekmezovic T, Stojsavljevic N, Kostic J, Dujmovic Basuroski I, Mesaros S, et al. Predictive value of health-related quality of life in progression of disability and depression in persons with multiple sclerosis: a 3-year study. Acta Neurol Belg. 2013;113(4):403–9.

    Article  PubMed  Google Scholar 

  68. Bambara JK, Turner AP, Williams RM, Haselkorn JK. Perceived social support and depression among veterans with multiple sclerosis. Disabil Rehabil. 2011;33(1):1–8.

    Article  PubMed  Google Scholar 

  69. Williams RM, Turner AP, Hatzakis Jr M, Rodriquez AA, Chu S, Bowen JD, et al. Social support among veterans with multiple sclerosis. Rehabil Psychol. 2004;49(2):106–13.

    Article  Google Scholar 

  70. Mohr DC, Classen C, Barrera Jr M. The relationship between social support, depression and treatment for depression in people with multiple sclerosis. Psychol Med. 2004;34(3):533–41.

    Article  CAS  PubMed  Google Scholar 

  71. Ploughman M, Harris C, Wallack EM, Drodge O, Beaulieu S, Mayo N, et al. Predictors of exercise participation in ambulatory and non-ambulatory older people with multiple sclerosis. Peer J. 2015;3:e1158.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Suh Y, Motl RW, Mohr DC. Physical activity, disability, and mood in the early stage of multiple sclerosis. Disabil Health J. 2010;3(2):93–8.

    Article  PubMed  Google Scholar 

  73. Fragoso YD, Adoni T, Anacleto A, da Gama PD, Goncalves MV, Matta AP, et al. Recommendations on diagnosis and treatment of depression in patients with multiple sclerosis. Pract Neurol. 2014;14(4):206–9.

    Article  PubMed  Google Scholar 

  74. Marrie RA, Hanwell H. General health issues in multiple sclerosis: comorbidities, secondary conditions, and health behaviors. Continuum. 2013;19(4):1046–57.

    PubMed  Google Scholar 

  75. Bischoff C, Schreiber H, Bergmann A. Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment. J Neurol. 2012;259(11):2347–53.

    Article  PubMed  Google Scholar 

  76. Beal CC, Stuifbergen AK, Brown A. Depression in multiple sclerosis: a longitudinal analysis. Arch Psychiatr Nurs. 2007;21(4):181–91.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci. 2009;277 Suppl 1:S37–41.

    Article  PubMed  Google Scholar 

  78. Strober LB, Arnett PA. Depression in multiple sclerosis: the utility of common self-report instruments and development of a disease-specific measure. J Clin Exp Neuropsychol. 2015;37(7):722–32.

    Article  PubMed  Google Scholar 

  79. Gunzler DD, Perzynski A, Morris N, Bermel R, Lewis S, Miller D. Disentangling multiple sclerosis and depression: an adjusted depression screening score for patient-centered care. J Behav Med. 2015;38(2):237–50.

    Article  PubMed  Google Scholar 

  80. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284–92.

    Article  PubMed  Google Scholar 

  81. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147(11):1493–7.

    Article  CAS  PubMed  Google Scholar 

  82. Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69(6):942–9.

    Article  CAS  PubMed  Google Scholar 

  83. Ehde DM, Kraft GH, Chwastiak L, Sullivan MD, Gibbons LE, Bombardier CH, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008;30(1):40–8.

    Article  PubMed  Google Scholar 

  84. Julian LJ, Mohr DC. Cognitive predictors of response to treatment for depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2006;18(3):356–63.

    Article  PubMed  Google Scholar 

  85. Foley FW, Bedell JR, LaRocca NG, Scheinberg LC, Reznikoff M. Efficacy of stress-inoculation training in coping with multiple sclerosis. J Consult Clin Psychol. 1987;55(6):919–22.

    Article  CAS  PubMed  Google Scholar 

  86. Moss-Morris R, Dennison L, Landau S, Yardley L, Silber E, Chalder T. A randomized controlled trial of cognitive behavioral therapy (CBT) for adjusting to multiple sclerosis (the saMS trial): does CBT work and for whom does it work? J Consult Clin Psychol. 2013;81(2):251–62.

    Article  PubMed  Google Scholar 

  87. Larcombe NA, Wilson PH. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. Br J Psychiatry. 1984;145:366–71.

    Article  CAS  PubMed  Google Scholar 

  88. Lincoln NB, Yuill F, Holmes J, Drummond AE, Constantinescu CS, Armstrong S, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult Scler. 2011;17(10):1250–7.

    Article  PubMed  Google Scholar 

  89. Graziano F, Calandri E, Borghi M, Bonino S. The effects of a group-based cognitive behavioral therapy on people with multiple sclerosis: a randomized controlled trial. Clin Rehabil. 2014;28(3):264–74.

    Article  PubMed  Google Scholar 

  90. Messmer Uccelli M, Mancuso Mohr L, Battaglia MA, Zagami P, Mohr DC. Peer support groups in multiple sclerosis: current effectiveness and future directions. Mult Scler. 2004;10(1):80–4.

    Article  CAS  PubMed  Google Scholar 

  91. Mohr DC, Hart SL, Julian L, Catledge C, Honos-Webb L, Vella L, et al. Telephone-administered psychotherapy for depression. Arch Gen Psychiatry. 2005;62(9):1007–14.

    Article  PubMed  Google Scholar 

  92. Mohr DC, Likosky W, Bertagnolli A, Goodkin DE, Van Der Wende J, Dwyer P, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol. 2000;68(2):356–61.

    Article  CAS  PubMed  Google Scholar 

  93. Ehde DM, Elzea JL, Verrall AM, Gibbons LE, Smith AE, Amtmann D. Efficacy of a telephone-delivered self-management intervention for persons with multiple sclerosis: a randomized controlled trial with a one-year follow-up. Arch Phys Med Rehabil. 2015;96(11):1945–58. e1942.

    Article  PubMed  Google Scholar 

  94. Moss-Morris R, McCrone P, Yardley L, van Kessel K, Wills G, Dennison L. A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue. Behav Res Ther. 2012;50(6):415–21.

    Article  PubMed  Google Scholar 

  95. Fischer A, Schroder J, Vettorazzi E, Wolf OT, Pottgen J, Lau S, et al. An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial. Lancet Psychiatry. 2015;2(3):217–23.

    Article  PubMed  Google Scholar 

  96. Mohr DC, Ho J, Duffecy J, Reifler D, Sokol L, Burns MN, et al. Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial. JAMA. 2012;307(21):2278–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Dalgas U, Stenager E, Jakobsen J, Petersen T, Hansen HJ, Knudsen C, et al. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. Mult Scler. 2010;16(4):480–90.

    Article  CAS  PubMed  Google Scholar 

  98. Cakt BD, Nacir B, Genc H, Saracoglu M, Karagoz A, Erdem HR, et al. Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. Am J Phys Med Rehabil. 2010;89(6):446–57.

    Article  PubMed  Google Scholar 

  99. Turner AP, Hartoonian N, Sloan AP, Benich M, Kivlahan DR, Hughes C, et al. Improving fatigue and depression in individuals with multiple sclerosis using telephone-administered physical activity counseling. J Consult Clin Psychol. 2016;84(4):297–309.

    Article  PubMed  Google Scholar 

  100. Bombardier CH, Ehde DM, Gibbons LE, Wadhwani R, Sullivan MD, Rosenberg DE, et al. Telephone-based physical activity counseling for major depression in people with multiple sclerosis. J Consult Clin Psychol. 2013;81(1):89–99.

    Article  PubMed  Google Scholar 

  101. Pilutti LA, Dlugonski D, Sandroff BM, Klaren R, Motl RW. Randomized controlled trial of a behavioral intervention targeting symptoms and physical activity in multiple sclerosis. Mult Scler. 2014;20(5):594–601.

    Article  CAS  PubMed  Google Scholar 

  102. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007;13(1):67–72.

    Article  CAS  PubMed  Google Scholar 

  103. Hartoonian N, Terrill AL, Beier ML, Turner AP, Day MA, Alschuler KN. Predictors of anxiety in multiple sclerosis. Rehabil Psychol. 2015;60(1):91–8.

    Article  PubMed  Google Scholar 

  104. Dahl OP, Stordal E, Lydersen S, Midgard R. Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trondelag County, Norway. Mult Scler. 2009;15(12):1495–501.

    Article  PubMed  Google Scholar 

  105. Terrill AL, Hartoonian N, Beier M, Salem R, Alschuler K. The 7-item generalized anxiety disorder scale as a tool for measuring generalized anxiety in multiple sclerosis. Int J MS Care. 2015;17(2):49–56.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Askari F, Ghajarzadeh M, Mohammadifar M, Azimi A, Sahraian MA, Owji M. Anxiety in patients with multiple sclerosis: association with disability, depression, disease type and sex. Acta Med Iran. 2014;52(12):889–92.

    PubMed  Google Scholar 

  107. Burns MN, Nawacki E, Siddique J, Pelletier D, Mohr DC. Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med. 2013;75(1):76–82.

    Article  CAS  PubMed  Google Scholar 

  108. Uguz F, Akpinar Z, Ozkan I, Tokgoz S. Mood and anxiety disorders in patients with multiple sclerosis. Int J Psychiatry Clin Pract. 2008;12(1):19–24.

    Article  PubMed  Google Scholar 

  109. Theaudin M, Romero K, Feinstein A. In multiple sclerosis anxiety, not depression, is related to gender. Mult Scler. 2016;22(2):239–44.

    Article  PubMed  Google Scholar 

  110. Bogart KR. Disability identity predicts lower anxiety and depression in multiple sclerosis. Rehabil Psychol. 2015;60(1):105–9.

    Article  PubMed  Google Scholar 

  111. Beiske AG, Svensson E, Sandanger I, Czujko B, Pedersen ED, Aarseth JH, et al. Depression and anxiety amongst multiple sclerosis patients. Eur J Neurol. 2008;15(3):239–45.

    Article  CAS  PubMed  Google Scholar 

  112. Garfield AC, Lincoln NB. Factors affecting anxiety in multiple sclerosis. Disabil Rehabil. 2012;34(24):2047–52.

    Article  CAS  PubMed  Google Scholar 

  113. Feinstein A, O’Connor P, Gray T, Feinstein K. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler. 1999;5(5):323–6.

    Article  CAS  PubMed  Google Scholar 

  114. Brown RF, Valpiani EM, Tennant CC, Dunn SM, Sharrock M, Hodgkinson S, et al. Longitudinal assessment of anxiety, depression, and fatigue in people with multiple sclerosis. Psychol Psychother. 2009;82(Pt 1):41–56.

    Article  CAS  PubMed  Google Scholar 

  115. O Donnchadha S, Burke T, Bramham J, O’Brien MC, Whelan R, Reilly R, et al. Symptom overlap in anxiety and multiple sclerosis. Mult Scler. 2013;19(10):1349–54.

    Article  PubMed  Google Scholar 

  116. Labuz-Roszak B, Kubicka-Baczyk K, Pierzchala K, Machowska-Majchrzak A, Skrzypek M. Fatigue and its association with sleep disorders, depressive symptoms and anxiety in patients with multiple sclerosis. Neurol Neurochir Pol. 2012;46(4):309–17.

    PubMed  Google Scholar 

  117. Amtmann D, Askew RL, Kim J, Chung H, Ehde DM, Bombardier CH, et al. Pain affects depression through anxiety, fatigue, and sleep in multiple sclerosis. Rehabil Psychol. 2015;60(1):81–90.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Goretti B, Viterbo RG, Portaccio E, Niccolai C, Hakiki B, Piscolla E, et al. Anxiety state affects information processing speed in patients with multiple sclerosis. Neurol Sci. 2014;35(4):559–63.

    Article  PubMed  Google Scholar 

  119. Stenager E, Knudsen L, Jensen K. Multiple sclerosis: correlation of anxiety, physical impairment and cognitive dysfunction. Ital J Neurol Sci. 1994;15(2):97–101.

    Article  CAS  PubMed  Google Scholar 

  120. Akbar N, Honarmand K, Feinstein A. Self-assessment of cognition in multiple sclerosis: the role of personality and anxiety. Cogn Behav Neurol. 2011;24(3):115–21.

    Article  PubMed  Google Scholar 

  121. Lester K, Stepleman L, Hughes M. The association of illness severity, self-reported cognitive impairment, and perceived illness management with depression and anxiety in a multiple sclerosis clinic population. J Behav Med. 2007;30(2):177–86.

    Article  PubMed  Google Scholar 

  122. McKay KA, Tremlett H, Fisk JD, et al. Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: a prospective multisite study. Mult Scler. 2016;22(5):685–93.

    Article  PubMed  Google Scholar 

  123. Turner AP, Williams RM, Sloan AP, Haselkorn JK. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. Rehabil Psychol. 2009;54(1):116–21.

    Article  PubMed  Google Scholar 

  124. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med. 2001;23(2):125–32.

    Article  CAS  PubMed  Google Scholar 

  125. Berrigan LI, Fisk JD, Patten SB, et al. Health-related quality of life in multiple sclerosis: direct and indirect effects of comorbidity. Neurology. 2016.

  126. Hayter AL, Salkovskis PM, Silber E, Morris RG. The impact of health anxiety in patients with relapsing remitting multiple sclerosis: misperception, misattribution and quality of life. Br J Clin Psychol. 2016.

  127. Poder K, Ghatavi K, Fisk JD, Campbell TL, Kisely S, Sarty I, et al. Social anxiety in a multiple sclerosis clinic population. Mult Scler. 2009;15(3):393–8.

    Article  CAS  PubMed  Google Scholar 

  128. Janssens AC, van Doorn PA, de Boer JB, van der Meche FG, Passchier J, Hintzen RQ. Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression, and disease-related distress. J Clin Epidemiol. 2004;57(2):180–6.

    Article  PubMed  Google Scholar 

  129. Glanz BI, Degano IR, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health. 2012;15(8):1029–35.

    Article  PubMed  Google Scholar 

  130. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, D.C.: American Psychiatric Association; 1994.

    Google Scholar 

  131. • Fiest KM, Walker JR, Bernstein CN, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016;5:12–26. This was a systematic review to determine the overall effect of psychological and pharmacological treatments for depression or anxiety in persons with MS. Of 1753 abstracts screened, 21 articles reporting on 13 unique clinical trials met the inclusion criteria. The review concluded that pharmacological and psychological treatments for depression were effective in reducing depressive symptoms in MS. The data are insufficient to determine the effectiveness of treatments for anxiety.

  132. Mohr DC, Cox D, Merluzzi N. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications. Mult Scler. 2005;11(2):182–5.

    Article  PubMed  Google Scholar 

  133. Kolahkaj B, Zargar F. Effect of mindfulness-based stress reduction on anxiety, depression and stress in women with multiple sclerosis. Nurs Midwifery Stud. 2015;4(4):e29655.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Mackay AM, Buckingham R, Schwartz RS, Hodgkinson S, Beran RG, Cordato DJ. The effect of biofeedback as a psychological intervention in multiple sclerosis: a randomized controlled study. Int J MS Care. 2015;17(3):101–8.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Nordin L, Rorsman I. Cognitive behavioural therapy in multiple sclerosis: a randomized controlled pilot study of acceptance and commitment therapy. J Rehabil Med. 2012;44(1):87–90.

    Article  PubMed  Google Scholar 

  136. Sajatovic M. Bipolar disorder: disease burden. Am J Manag Care. 2005;11(3 Suppl):S80–4.

    PubMed  Google Scholar 

  137. Marrie RA, Patten SB, Tremlett H, et al. Sex differences in comorbidity at diagnosis of multiple sclerosis: a population-based study. Neurology. 2016.

  138. Carta MG, Moro MF, Lorefice L, Picardi A, Trincas G, Fenu G, et al. Multiple sclerosis and bipolar disorders: the burden of comorbidity and its consequences on quality of life. J Affect Disord. 2014;167:192–7.

    Article  CAS  PubMed  Google Scholar 

  139. Johansson V, Lundholm C, Hillert J, Masterman T, Lichtenstein P, Landen M, et al. Multiple sclerosis and psychiatric disorders: comorbidity and sibling risk in a nationwide Swedish cohort. Mult Scler. 2014;20(14):1881–91.

    Article  PubMed  Google Scholar 

  140. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck Jr PE, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157(11):1873–5.

    Article  CAS  PubMed  Google Scholar 

  141. Zimmerman M, Galione JN. Screening for bipolar disorder with the Mood Disorders Questionnaire: a review. Harv Rev Psychiatry. 2011;19(5):219–28.

    Article  PubMed  Google Scholar 

  142. Hotier S, Maltete D, Bourre B, Jegouzo X, Bourgeois V, Guillin O. A manic episode with psychotic features improved by methylprednisolone in a patient with multiple sclerosis. Gen Hosp Psychiatry. 2015;37(6):621.e1–622.

    Article  Google Scholar 

  143. Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(2):174–81.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Hatzakis Jr M, Haselkorn J, Williams R, Turner A, Nichol P. Telemedicine and the delivery of health services to veterans with multiple sclerosis. J Rehabil Res Dev. 2003;40(3):265–82.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rehabilitation Care Service, VA Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, WA, 98108, USA

    Aaron P. Turner, Jodie K. Haselkorn & Alicia P. Sloan

  2. Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA

    Aaron P. Turner, Kevin N. Alschuler, Jodie K. Haselkorn & Dawn M. Ehde

  3. Department of Neurology, University of Washington, Seattle, WA, USA

    Kevin N. Alschuler

  4. Department of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, MD, USA

    Abbey J. Hughes & Meghan Beier

  5. Department of Epidemiology, University of Washington, Seattle, WA, USA

    Jodie K. Haselkorn

Authors
  1. Aaron P. Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin N. Alschuler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abbey J. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meghan Beier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jodie K. Haselkorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alicia P. Sloan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dawn M. Ehde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aaron P. Turner.

Ethics declarations

Conflict of Interest

Aaron P. Turner, Kevin N. Alschuler, Abbey J. Hughes, Meghan Beier, Jodie K. Haselkorn, Alicia P. Sloan, and Dawn M. Ehde declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical collection on Demyelinating Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Turner, A.P., Alschuler, K.N., Hughes, A.J. et al. Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder. Curr Neurol Neurosci Rep 16, 106 (2016). https://doi.org/10.1007/s11910-016-0706-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-016-0706-x

Keywords

Search

Navigation